Jade Biosciences, Inc.
No enriched coverage for $JBIO in the last 7 days.
No SEC Form 4 filings for $JBIO in the last 30 days.
See all $JBIO insider activity →HC Wainwright & Co. reiterated a Buy rating on Jade Biosciences with a $55 price target, implying a 291.5% upside from the Sep 30 close. The rating is based on the company's strong pipeline, particularly JADE101 in Phase 1 trials, and favorable valuation metrics according to the analyst.
Wedbush reiterated an Outperform rating and $47 price target for Jade Biosciences (JBIO) after positive preclinical data for JADE301. The stock is up 54% over the past year. Analysts expect key data readouts in 2027. Jade Biosciences has no debt and a strong cash position. Multiple analysts have raised price targets and maintained positive ratings.
Jade Biosciences (JBIO) is advancing JADE301, an investigational antibody, toward a Phase 1 trial for dermatomyositis after preclinical studies showed it selectively blocks IFN-Beta. The drug demonstrated high potency and extended half-life, with plans for a trial in Q4 2026. JBIO stock closed at $14.18, down 1.18%.
Recent JBIO coverage spans financial news, earnings and corporate actions.
HC Wainwright & Co. reiterated a Buy rating on Jade Biosciences with a $55 price target, implying a 291.5% upside from the Sep 30 close. The rating is based on the company's strong pipeline, particularly JADE101 in Phase 1 trials, and favorable valuation metrics according to the analyst.
Positive preclinical data may lift JBIO as investors anticipate upcoming Phase 1 trial.
The trial initiation is a key milestone that could lift the stock if early data are positive.
Positive preclinical results and a clear Phase 1 timeline suggest near‑term upside potential.
The filing combines cash runway guidance into Q4 2028 with multiple clinical-program updates, which can re-rate near-term risk and financing expectations.
AlphAI scores every news story that mentions JBIO with an AI model for sentiment and relevance, and aggregates insider trades from Jade Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HC Wainwright & Co. reiterated a Buy rating on Jade Biosciences with a $55 price target, implying a 291.5% upside from the Sep 30 close. The rating is based on the company's strong pipeline, particularly JADE101 in Phase 1 trials, and favorable valuation metrics according to the analyst.
2 min readWedbush reiterated an Outperform rating and $47 price target for Jade Biosciences (JBIO) after positive preclinical data for JADE301. The stock is up 54% over the past year. Analysts expect key data readouts in 2027. Jade Biosciences has no debt and a strong cash position. Multiple analysts have raised price targets and maintained positive ratings.
2 min readJade Biosciences (JBIO) is advancing JADE301, an investigational antibody, toward a Phase 1 trial for dermatomyositis after preclinical studies showed it selectively blocks IFN-Beta. The drug demonstrated high potency and extended half-life, with plans for a trial in Q4 2026. JBIO stock closed at $14.18, down 1.18%.
2 min readJade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 30, 2026, Jade Biosciences, Inc. (“Jade”) announced preclinical data characterizing JADE301, its anti-interferon beta (“IFN-ß”) monoclonal antibody in development for dermatomyositis (“DM”), a rare, chronic and debilitating autoimmune disease
2 min readJade Biosciences (JBIO) reported Q2 2026 net loss of $55.8M and cash, cash equivalents and investments of $461.2M as of June 30, 2026, saying it funds operations into Q4 2028. R&D was $50.1M and G&A $8.9M. The company advanced JADE101 to Phase 2/3 and updated progress on JADE201 and JADE301.
1 min readJade Biosciences (NASDAQ: JBIO) reported net losses of $55.8M for Q2 2026 and $96.1M for the first half of 2026, versus $32.1M and $70.3M a year earlier. Cash and investments totaled $461.2M at June 30, 2026 after a June equity financing. The company advanced JADE101, JADE201, and JADE301.
6 min readJade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update • Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy
6 min readJade Biosciences reported that its Q2 net loss widened as costs increased, according to the company. The update highlights higher operating expenses affecting profitability. Investors may monitor the cost trajectory and future funding needs as the company reports ongoing quarterly results.
1 min readJade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K NASDAQ false 0001798749 0001798749 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Ju
4 min readJade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K NASDAQ false 0001798749 0001798749 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Ju
3 min read
